• Interim 2017 results and business update

    - Ramp-up of industrial capacity underway, with some adjustments to ensure GMP compliance
    - Impacts on the provisional schedule: delay of approximately 6monts for priority US filings
    - ...

    Read more
  • Business update

    Crossject is continuing its strategy announced in November 2016, focusing on the development of emergency drugs and the signing of distribution licensing agreements, particularly in the United States.
    Read the Press Release

    Read more


  • 01/01/2017

    Copenhagen European Midcap Event

    Meet us in Copenhagen, Mai 18th 2017, during the European Midcap Event.

    Read more
  • 01/01/2017

    Large and Midcap Event 2017

    Crossject will meet institutional investors on the occasion of Large and Midcap Event in Paris, October 5 and 6, 2017.

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos